Enhancing Patient Safety through the Use of a Pharmaceutical Glass Designed To Prevent Cracked Containers

References

1. 1.↵
   U.S. National Archives and Records Administration. Title 21. Drug Product Containers and Closures. Section 211.94 In Code of Federal Regulations; 2016.
2. 2.↵
   U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Container Closure Systems for Packaging Human Drugs and Biologics; 1999.
3. 3.↵
   1. Maki D. G.,
   2. Goldmnan D. A.,
   3. Rhame F. S.

   Infection Control in Intravenous Therapy. Annals of Internal Medicine 1973, 79 (6), 867–887.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Wang S. A.,
   2. Tokars J. I.,
   3. Bianchine P. J.,
   4. Carson L. A.,
   5. Arduino M. J.,
   6. Smith A. L.,
   7. Hansen N. C.,
   8. Fitzgerald E. A.,
   9. Epstein J. S.,
   10. Jarvis W. R.

   Enterobacter cloacae Bloodstream Infections Traced to Contaminated Human Albumin. Clinical Infectious Diseases 2000, 30 (1), 35–40.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Bhakdi S.,
   2. Krämer I.,
   3. Siegel E.,
   4. Jansen B.,
   5. Exner M.

   Use of Quantitative Microbiological Analyses to Trace Origin of Contamination of Parenteral Nutrition Solutions. Medical Microbiology and Immunology 2012, 201 (2), 231–237.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Schaut R. A.,
   2. Weeks W. P.

   Historical Review of Glasses Used for Parenteral Packaging. PDA J. Pharm. Sci. Technol. 2017, 71 (4), 279–296.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Felton L.

   1. Akers M. J.

   Parenteral Preparations. In Remington: Essentials of Pharmaceutics; Felton L., Ed.; Pharmaceutical Press: London, U.K., 2013; pp 495–532.
8. 8.↵
   1. Eakins M. N.

   Parenteral Products: Pharmacopeial Control of Containers, Storage and Distribution. Pharmacopeial Forum 2011, 3, 4.

   OpenUrl
9. 9.↵
   1. Kuehn S. E.

   Clash of the Titans: Super-Rivals Glass and Plastic Square Off for Patient Safety. Pharmaceutical Manufacturing 2014 (October), 3–9.
10. 10.↵
    PDA Technical Report 43. Identification and Classification of Nonconformities in Molded and Tubular Glass Containers for Pharmaceutical Manufacturing: Covering Ampoules, Bottles, Cartridges, Syringes and Vials. Parenteral Drug Association: Bethesda, MD, 2013.
11. 11.↵
    1. Sack R. A.

    Epidemic of Gram-Negative Organism Septicemia Subsequent to Elective Operation. American Journal of Obstetrics and Gynecology 1970, 107 (3), 394–399.

    OpenUrlPubMedWeb of Science
12. 12.↵
    1. Robertson M. H.

    Fungi in Fluids—A Hazard of Intravenous Therapy. Journal of Medical Microbiology 1970, 3 (1), 99–102.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Maddocks A. C.,
    2. Raine G.

    Contaminated Drip Fluids. British Medical Journal 1972, 2 (5807), 231.

    OpenUrlFREE Full Text
14. 14.↵
    1. Elin R. J.,
    2. Lundberg W. B.,
    3. Schmidt P. J.

    Evaluation of Bacterial Contamination in Blood Processing. Transfusion 1975, 15 (3), 260–265.

    OpenUrl
15. 15.↵
    1. Daisy J. A.,
    2. Abrutyn E. A.,
    3. Mac G. R.

    Inadvertent Administration of Intravenous Fluids Contaminated With Fungus. Annals of Internal Medicine 1979, 91 (4), 563–565.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Frechette V. D.

    Failure Analysis of Brittle Materials; American Ceramic Society, Inc.: Westerville, OH, 1990; p 116.
17. 17.↵
    1. Bloomfield S.,
    2. Exner M.,
    3. Flemming H.-C.,
    4. Goroncy-Bermes P.,
    5. Hartemann P.,
    6. Heeg P.,
    7. Ilschner C.,
    8. Krämer I.,
    9. Merkens W.,
    10. Oltmanns P.,
    11. Rotter M.,
    12. Rutala W. A.,
    13. Sonntag H.-G.,
    14. Trautmann M.

    Lesser-Known or Hidden Reservoirs of Infection and Implications for Adequate Prevention Strategies: Where To Look and What To Look for. GMS Hygiene and Infection Control 2015, 10, 1–14.

    OpenUrl
18. 18.↵
    1. Nema S.,
    2. Ludwig J. D.

    1. Swift R.

    Glass Containers for Parenteral Products. In Pharmaceutical Dosage Forms—Parenteral Medications, 3rd ed.; Nema S., Ludwig J. D., Eds.; CRC Press: Boca Raton, FL, 2012; Vol. 1, pp 287–304.

    OpenUrl
19. 19.↵
    USP Committee of Revision. <1207> Package Integrity Evaluation—Sterile Products. In The United States Pharmacopeia, Thirty-ninth Revision; US Pharmacopeia, 2016.
20. 20.↵
    1. Maki D. G.,
    2. Martin W. T.

    Nationwide Epidemic of Septicemia Caused by Contaminated Infusion Products. IV. Growth of Microbial Pathogens in Fluids for Intravenous Infusion. Journal of Infectious Diseases 1975, 131 (3), 267–272.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Phillips I.,
    2. Meers P.D.,
    3. D'Arcy P.F.

    Microbiological Hazards of Infusion Therapy, Phillips I., Meers P.D., D'Arcy P.F., Eds.; Springer: Amsterdam, 1976; p 186.
22. 22.↵
    Pharmaceutical Technology Editors. Injectables to Show Double-Digit Growth Through 2020 PharmTech.com [Online], 2015. http://www.pharmtech.com/injectables-show-double-digit-growth-through-2020.
23. 23.↵
    USP Committee of Revision. <1207.2> Package Integrity Leak Test Technologies. In The United States Pharmacopeia, Thirty-ninth Revision; US Pharmacopeia, 2016.
24. 24.↵
    1. Uhlmann D.

    1. Gardon R.

    Thermal Tempering of Glass. In Elasticity and Strength in Glasses: Glass: Science and Technology, Uhlmann D., Ed.; Elsevier Science: Amsterdam, 2012; pp 145–213.
25. 25.↵
    1. Bradt R. C.,
    2. Munz D.,
    3. Sakai M.,
    4. White K. W.

    1. Tandon R.,
    2. Glass S. J.

    Controlling the Fragmentation Behavior of Stressed Glass. In Fracture Mechanics of Ceramics: Active Materials, Nanoscale Materials, Composites, Glass and Fundamentals, Bradt R. C., Munz D., Sakai M., White K. W., Eds.; Springer: Boston, MA, 2005; pp 77–91.
26. 26.
    1. Lawn B.,
    2. Marshall D.

    Contact Fracture Resistance of Physically and Chemically Tempered Glass Plates—A Theoretical Model. Physics and Chemistry of Glasses 1977, 18 (1), 7–18.

    OpenUrl
27. 27.↵
    1. Gy R.

    Ion Exchange for Glass Strengthening. Materials Science and Engineering B 2008, 149 (2), 159–165.

    OpenUrl
28. 28.↵
    1. Schaut R. A.,
    2. Peanasky J. S.,
    3. DeMartino S. E.,
    4. Schiefelbein S. L.

    A New Glass Option for Parenteral Packaging. PDA J. Pharm. Sci. Technol. 2014, 68 (5), 527–534.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Timmons C.,
    2. Liu C. Y.,
    3. Merkle S.

    Particulate Generation Mechanisms during Bulk Filling and Mitigation via New Glass Vial. PDA J. Pharm. Sci. Technol. 2017, 71 (5), 379–392.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Clark C. C.,
    2. Yudenfriend H.,
    3. Redner A. S.

    Laceration and Ejection Dangers of Automotive Glass, and the Weak Standards Involved. The Strain Fracture Test. Annual Proceedings/Association for the Advancement of Automotive Medicine 2000, 44, p 117–132.